Century Report
The Century Report: February 26, 2026
The 10-Second Scan * MindRank dosed the first patient in a Phase III trial of MDR-001, an AI-designed oral GLP-1 receptor agonist for obesity and diabetes that reached this stage in 4.5 years from project initiation. * Five pharmaceutical companies launched the ADMET Network, pooling 80% of their proprietary drug absorption